The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

The average age of men who get diagnosed is 67.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients. Prostate cancer is the most common cancer among men ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

At 77 years old, Tyson Johnson has been in treatment for metastatic prostate cancer for more than 20 years. “I’m the healthiest dead man you’ve ever seen,” the Carthage resident said jokingly as he ...

Prostate cancer is the second most common cancer diagnosis in men. 1 in 8 men will be diagnosed with the disease during their lifetime. Dr. Jose Avita from the New Mexico Cancer Center talked about ...